Corvus Pharmaceuticals Inc. said its lead product CPI-444, as a single agent and in combination with atezolizumab, showed anti-tumor activity, based on interim results from the renal cell carcinoma, or RCC, and non-small cell lung cancer, or NSCLC, expansion cohorts in an ongoing phase 1/1b study.
The treatment demonstrated anti-tumor activity in patients resistant or refractory to prior treatment with anti-programmed death-ligand 1, or PD-(L)1, antibodies and patients with PD-L1 negative tumors.
Among 22 evaluable RCC patients, best tumor response data showed two confirmed partial responses. In this group, 16 patients achieved stable disease, including six who experienced minor regressions.
Best tumor response data for NSCLC patients showed two partial responses out of 34 evaluable patients. In this group, 22 patients achieved stable disease, including four who experienced minor regressions.
Corvus said CPI-444 remains well tolerated, with observed adverse events similar to previous reports.
CPI-444 is a checkpoint inhibitor that obstructs adenosine in the tumor microenvironment. Atezolizumab is a monoclonal antibody targeting and binding to PD-L1. Atezolizumab is also known as Tecentriq, which is developed by Roche Holding Ltd. unit Genentech Inc.